Tissue-specific untargeted 1H-NMR metabolomics reveals no adverse metabolic effects of daily intrabuccal cannabidiol (CBD) in healthy mice
Cannabidiol (CBD) has attracted renewed scientific attention for its therapeutic potential in human metabolism. However, the metabolic effects of CBD treatment remain incompletely understood. This study investigated tissue-specific metabolic alterations in the brain, liver, and kidneys of Kramnik mice after 2 weeks of daily CBD treatment using an untargeted proton magnetic resonance ( 1 H-NMR) metabolomics approach. Unsupervised principal component analysis (PCA) revealed minimal biological variation between the CBD-treated and control groups. The most notable, albeit minor, changes were observed in the brain and were associated with decreased signaling and neuroenergetics. The liver showed changes in sugar metabolism, and the kidneys showed only minor changes in phenylalanine levels. Collectively, our results suggest a more metabolically balanced state in the mice. These data support the adjunctive use of CBD, as no adverse metabolic effects were observed in the brain, liver, or kidneys.